Applied Medical Resources Corporation
$1.9M 2,197 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. reported $1,912,525.65 across General Payments, Research, and Ownership to 146 physicians and teaching hospitals across 198 transactions.
- $1.9M Top quartile payer
- All-tracks total
- 198 Above-median volume
- Transactions
- 146 Above-median reach
- Recipients
- +$134.5K
- General Payments vs PY2023
Spark Therapeutics, Inc. reported $1,912,525.65 across all CMS Open Payments tracks (General + Research + Ownership) to 146 physicians and teaching hospitals in Program Year 2024 - ranking #460 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,145,034.82, averaging $13.1K per recipient.
How Spark Therapeutics, Inc.'s $1.9M all-tracks total breaks down
Spark Therapeutics, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
35/100
Total payments
F
28/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer spark-therapeutics-inc Spark Therapeutics, Inc.
$1.9M · #460/1,925 · 0.0% industry · PY2024
- TOT $1.9M
- RANK #460
- SHARE 0.0%
- TXN 198
- RCP 146
- CAT 7
- GEN $1.1M
- ΔGEN +$134.5K
- TOP1 75.2%
- PY 2024
Volume peers
Nearest volume peer: Applied Medical Resources Corporation ($1.9M)
Spark Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Spark Therapeutics, Inc.'s CMS-reported General Payments increased by $134.5K (+13.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SPARK THERAPEUTICS, INC.PY2023: SPARK THERAPEUTICS, INC.PY2024: Spark Therapeutics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,010,530.84
- PY2024
- $1,145,034.82
What the Data Shows for Spark Therapeutics, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Spark Therapeutics, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Royalty or License" leads the 7-category general-payment breakdown below at $1.0M (89.5% of General Payments, 25 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Spark Therapeutics, Inc. made 7 types of general payments. "Royalty or License" is the largest category at $1.0M, 89.5% of General Payments.
Spark Therapeutics, Inc. reports 7 general-payment categories - the top three are Royalty or License (89.5%), Consulting Fee (5.4%), and Compensation for Services Other Than Consulting (3.1%). The remaining 4 categories make up 2.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Spark Therapeutics, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $1.0M | 25 | 89.5% |
| Consulting Fee | $61.5K | 38 | 5.4% |
| Compensation for Services Other Than Consulting | $35.7K | 4 | 3.1% |
| Education | $12.0K | 2 | 1.0% |
| Travel and Lodging | $8.0K | 28 | 0.7% |
| Food and Beverage | $2.5K | 48 | 0.2% |
| Charitable Contribution | $1.0K | 1 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,073,656.54 (93.8%) of $1,145,034.82 in this company's General Payments records across 50 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Spark Therapeutics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
The Childrens Hospital of Philadelp
$861,354.10 across 22 reported transactions
- 2
Presbyterian Medical Center
$164,953.57 across 4 reported transactions
- 3
Daniel Claassen
$16,366.12 across 7 reported transactions
- 4
Sharon Popik
$15,600.00 across 3 reported transactions
- 5
Stephen Russell
$15,382.75 across 9 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Spark Therapeutics, Inc.'s spend rank (#460 of 1,925, top 24% by spend) and concentration rank (#272 of 1,838, top 15% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Viseon, Inc. : $146.3K total payments, HHI 5966
- Digital Diagnostics Inc. : $54.4K total payments, HHI 5924
- Vertical Orthopaedics, Inc. : $34.2K total payments, HHI 5923
- TheraMicro, Inc. : $14.0K total payments, HHI 5918
- ReShape Lifesciences Inc. : $5.8K total payments, HHI 5891
- Rebiotix Inc. : $114.1K total payments, HHI 5889
- Spark Therapeutics, Inc. (this company) : $1.1M total payments, HHI 5876
- Agile Devices, Inc. : $8.4K total payments, HHI 5847
- Hubly Incorporated : $205.53 total payments, HHI 5839
- New York Blood Center, Inc. : $184.6K total payments, HHI 5838
- Mylan Pharmaceuticals Inc. : $379.70 total payments, HHI 5777
- Novo Nordisk US Research & Development, Inc. : $7.8K total payments, HHI 5774
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Spark Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Spark Therapeutics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Spark Therapeutics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Acrotech Biopharma Inc.
$1.9M 1,589 recipients
Compare payment profiles
Vasorum USA Inc.
$1.9M 59 recipients
Compare payment profiles
Procyrion, Inc.
$1.9M 211 recipients
Compare payment profiles
Milestone Scientific Inc.
$1.9M 47 recipients
Compare payment profiles
Lantheus Medical Imaging, Inc.
$1.9M 2,496 recipients
Compare payment profiles
Put this to use
Spark Therapeutics, Inc. ranks #460 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See where Spark Therapeutics, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just Spark Therapeutics, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.